A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
NCT ID: NCT00175877
Last Updated: 2020-03-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
857 participants
INTERVENTIONAL
2005-06-30
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
NCT00160641
A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis
NCT00152386
Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis
NCT01197066
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
NCT00717236
A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
NCT00160602
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Certolizumab Pegol
All patients received Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) every two weeks, given as two 1 ml injections of CZP for at least six months and then 200 mg of CZP sc every two weeks, given as one 1 ml injection.
Certolizumab Pegol
Strength and Form: Lyophilized product reconstituted to 1 ml containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.
Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.
Duration: Until end of study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Certolizumab Pegol
Strength and Form: Lyophilized product reconstituted to 1 ml containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.
Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.
Duration: Until end of study.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* A secondary, non-inflammatory type of Arthritis (e.g. Osteoarthritis or Fibromyalgia) that in the Investigator's opinion is symptomatic enough to interfere with evaluation of the effect of CDP870 on the patient's primary diagnosis of Rheumatoid Arthritis
* Any concomitant biological therapy
* Any experimental therapy, within or outside a clinical trial
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
152
Huntsville, Alabama, United States
148
San Diego, California, United States
153
Danbury, Connecticut, United States
133
Ocala, Florida, United States
140
Orlando, Florida, United States
150
Orlando, Florida, United States
145
Sarasota, Florida, United States
136
Tampa, Florida, United States
157
Coeur d'Alene, Idaho, United States
155
Springfield, Illinois, United States
134
Wheaton, Maryland, United States
151
St Louis, Missouri, United States
156
Lincoln, Nebraska, United States
135
Charlotte, North Carolina, United States
147
Cleveland, Ohio, United States
158
Dayton, Ohio, United States
139
Charleston, South Carolina, United States
137
Austin, Texas, United States
143
San Antonio, Texas, United States
12
Buenos Aires, , Argentina
14
Capital Federal, , Argentina
1
Capital Federal, , Argentina
9
Capital Federal, , Argentina
8
Ciudad Autonoma de Buenos Aire, , Argentina
11
Córdoba, , Argentina
2
Córdoba, , Argentina
13
Quilmes, , Argentina
7
Rosario, , Argentina
10
San Miguel de Tucumán, , Argentina
6
Santa Fe, , Argentina
18
Malvern, , Australia
21
Maroochydore, , Australia
23
Perth, , Australia
179
Antwerp, , Belgium
199
Liège, , Belgium
177
Merksem, , Belgium
29
Pleven, , Bulgaria
221
Sofia, , Bulgaria
28
Sofia, , Bulgaria
30
Sofia, , Bulgaria
26
Stara Zagora, , Bulgaria
43
Newmarket, Ontario, Canada
32
Toronto, Ontario, Canada
39
Toronto, Ontario, Canada
35
Hamilton, , Canada
36
Kitchener, , Canada
201
Pointe-Claire, , Canada
31
Sainte-Foy, , Canada
203
Winnipeg, , Canada
190
Santiago, , Chile
49
Santiago, , Chile
44
Valdivia, , Chile
52
Rijeka, , Croatia
56
Brno, , Czechia
57
Ostrava Trebovice, , Czechia
187
Pilsen, , Czechia
55
Prague, , Czechia
60
Prague, , Czechia
61
Prague, , Czechia
58
Uherské Hradiště, , Czechia
62
Zlín, , Czechia
64
Pärnu, , Estonia
65
Tallinn, , Estonia
63
Tartu, , Estonia
68
Hyvinkää, , Finland
160
Montpellier, , France
71
Budapest, , Hungary
73
Budapest, , Hungary
75
Bupadest, , Hungary
191
Debrecen, , Hungary
76
Miskolc, , Hungary
74
Szolnok, , Hungary
79
Afula, , Israel
82
Ashkelon, , Israel
81
Haifa, , Israel
83
Haifa, , Israel
78
Ramat Gan, , Israel
77
Tel Aviv, , Israel
85
Ẕerifin, , Israel
86
Riga, , Latvia
88
Riga, , Latvia
92
Alytus, , Lithuania
89
Kaunas, , Lithuania
91
Klaipėda, , Lithuania
93
Panevezys, , Lithuania
90
Šiauliai, , Lithuania
94
Vilnius, , Lithuania
95
Mexicalli, , Mexico
96
Monterrey, , Mexico
103
Auckland, , New Zealand
101
Christchurch, , New Zealand
100
South Canterbury, , New Zealand
192
Tauranga, , New Zealand
107
Moscow, , Russia
113
Moscow, , Russia
222
Moscow, , Russia
223
Moscow, , Russia
224
Moscow, , Russia
109
Saint Petersburg, , Russia
111
Saint Petersburg, , Russia
112
Saint Petersburg, , Russia
193
Saint Petersburg, , Russia
110
Yaroslavl, , Russia
117
Belgrade, , Serbia
118
Belgrade, , Serbia
114
Niška Banja, , Serbia
115
Novi Sad, , Serbia
119
Bratislava, , Slovakia
121
Košice, , Slovakia
120
Piešťany, , Slovakia
122
Piešťany, , Slovakia
210
Dnipro, , Ukraine
209
Donetsk, , Ukraine
216
Donetsk, , Ukraine
213
Ivano-Frankivsk, , Ukraine
211
Kiev, , Ukraine
212
Kiev, , Ukraine
215
Kiev, , Ukraine
220
Kiev, , Ukraine
208
Symferopyl, , Ukraine
214
Zaporizhzhya, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Paul S, Marotte H, Kavanaugh A, Goupille P, Kvien TK, de Longueville M, Mulleman D, Sandborn WJ, Vande Casteele N. Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis. Clin Transl Sci. 2020 Jul;13(4):743-751. doi: 10.1111/cts.12760. Epub 2020 Apr 1.
Keystone EC, Combe B, Smolen J, Strand V, Goel N, van Vollenhoven R, Mease P, Landewe R, Fleischmann R, Luijtens K, van der Heijde D. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology (Oxford). 2012 Sep;51(9):1628-38. doi: 10.1093/rheumatology/kes082. Epub 2012 May 16.
van der Heijde D, Keystone EC, Curtis JR, Landewe RB, Schiff MH, Khanna D, Kvien TK, Ionescu L, Gervitz LM, Davies OR, Luijtens K, Furst DE. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. J Rheumatol. 2012 Jul;39(7):1326-33. doi: 10.3899/jrheum.111171. Epub 2012 May 15.
Curtis JR, Chen L, Luijtens K, Navarro-Millan I, Goel N, Gervitz L, Weinblatt M. Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. Arthritis Rheum. 2011 Aug;63(8):2203-8. doi: 10.1002/art.30387.
Curtis JR, Winthrop K, O'Brien C, Ndlovu MN, de Longueville M, Haraoui B. Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment. Arthritis Res Ther. 2017 Dec 15;19(1):276. doi: 10.1186/s13075-017-1466-y.
Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, Strand V, Vencovsky J, van der Heijde D. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009 Jun;68(6):797-804. doi: 10.1136/ard.2008.101659. Epub 2008 Nov 17.
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005-001350-24
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
C87028
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.